Link to this page
Biological and Environmental Research Ontology
Last uploaded:
December 23, 2022
| Id | http://purl.obolibrary.org/obo/NCIT_C1433
http://purl.obolibrary.org/obo/NCIT_C1433
|
|---|---|
| Preferred Name | Liarozole |
| Definitions |
An orally-active benzimidazole derivative with potential antineoplastic activity. As a retinoic acid metabolism blocking agent, liarozole inhibits cytochrome P450-dependent all-trans-retinoic acid (ATRA)-4-hydroxylase, resulting in an increase in endogenous ATRA production, inhibition of cell proliferation, and induction of cell differentiation. This agent also inhibits aromatase, the enzyme that catalyzes the final, rate-limiting step in estrogen biosynthesis.
|
| Type | http://www.w3.org/2002/07/owl#Class |
All Properties
| definition | An orally-active benzimidazole derivative with potential antineoplastic activity. As a retinoic acid metabolism blocking agent, liarozole inhibits cytochrome P450-dependent all-trans-retinoic acid (ATRA)-4-hydroxylase, resulting in an increase in endogenous ATRA production, inhibition of cell proliferation, and induction of cell differentiation. This agent also inhibits aromatase, the enzyme that catalyzes the final, rate-limiting step in estrogen biosynthesis. |
|---|---|
| prefLabel | Liarozole
|
| label | Liarozole
|
| Has_Salt_Form | |
| code | C1433
|
| prefixIRI | NCIT:C1433
|
| in_subset | |
| Preferred_Name | Liarozole
|
| FDA_UNII_Code | K0Q29TGV9Y
|
| Contributing_Source | FDA
|
| Chemical_Formula | C17H13ClN4
|
| Maps_To | Liarozole
|
| CAS_Registry | 115575-11-6
|
| Legacy Concept Name | Liarozole
|
| type | |
| ALT_DEFINITION | An anticancer drug that promotes differentiation by increasing the levels of retinoic acid within the tumor.
|
| Is_Value_For_GDC_Property | |
| subClassOf | |
| Semantic_Type |
Organic Chemical
Pharmacologic Substance
|
| UMLS_CUI | C0165479
|
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |